Eli Lilly and Co is increasing its efforts in the IBD field! Morphic, the biotechnology company, will be acquired for $3.2 billion.
Eli Lilly and Co will acquire Morphic, based in Waltham, Massachusetts, for $57 per share. Eli Lilly has made significant investments in this field to provide top-tier small molecule drugs.
Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
Monday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion.
US Stock Market Preview: US stocks under "tremendous pressure"? Strategist: the upcoming earnings season is crucial; Taiwan Semiconductor rose over 3% in pre-market trading, and the opening momentum set a new high.
The three major equity index futures rose before the market opening, and most growth tech stocks rose before the market opening; major events in the US stock market are happening one after another: inflation data and the start of the earnings season, and the market expects a signal of Fed interest rate cut; Intel rose nearly 4% before the market, and released a new generation of datacenter immersive liquid cooling solution.
GordonMD Global Investments Announces Radionetics Oncology's Strategic Agreement With Eli Lilly; Radionetics Receives $140M Upfront, Lilly Secures Exclusive Right To Acquire For $1B
GordonMD Global Investments Announces Radionetics Oncology's Strategic Agreement With Eli Lilly; Radionetics Receives $140M Upfront, Lilly Secures Exclusive Right To Acquire For $1B
Ideaya Stock Jumps After Positive Study Data From Cancer Study
Regeneron Pharmaceuticals Expects Its Q2 GAAP And Non-GAAP Financial Results Will Include A Pre-tax Charge Of ~$24M For Acquired In-process Research And Development, Impacting GAAP And Non-GAAP EPS By About $0.18 - 8K
Regeneron Pharmaceuticals Expects Its Q2 GAAP And Non-GAAP Financial Results Will Include A Pre-tax Charge Of ~$24M For Acquired In-process Research And Development, Impacting GAAP And Non-GAAP EPS By
Options Outlook: Taiwan Semiconductor's stock price has repeatedly hit new highs! The pre-performance options market tends to be bullish; Bank of America's performance on the day of earning release may have high probability of rising, and large orders sel
Options market bets on Netflix's performance with a daily fluctuation of 8.8%, but past performance fluctuations have been over 11%, and options value may be underestimated. The stock has fallen on more than half of the past 12 performance days, accounting for 58% of them. In the recent four performance days, Netflix's overall fluctuations were significant.
The US stock market continues to soar to new heights! From "Trump Trade" to "Interest Rate Cut Trade", the market welcomed two heavyweight signals this week.
With the release of weak job market data, the expectation of a Fed rate cut has been reignited, causing bond yields to rise and fall. Funds have poured back into technology stocks, and the Nasdaq and S&P 500 hit new highs together last Friday.
Eli Lilly Agrees To Buy Morphic For $57 Per Share In Cash, An Aggregate Of Approximately $3.2B, Acquisition To Expand Lilly's Immunology Pipeline With Oral Integrin Therapies
Eli Lilly Agrees To Buy Morphic For $57 Per Share In Cash, An Aggregate Of Approximately $3.2B, Acquisition To Expand Lilly's Immunology Pipeline With Oral Integrin Therapies
Latest report on active-management mutual funds in USA: Only 15 out of 1218 funds suffered losses.
The winning strategy of these top-ranked actively managed public funds is to heavily invest in the 'Seven Giants of the US Stock Market' that have caught onto the AI trend.
Will the "technology faith" be renewed during the US earnings season this week?
This time, Wall Street has high expectations for US stock earnings reports. FactSet predicts that the S&P 500 index will see a nearly 9% year-on-year growth in profits for the second quarter, with a chance to achieve the largest quarterly increase since early 2022.
Weekend Reading | How Johnson & Johnson Orthopedics' Empire Dream Was Shattered?
The opportunity for the pharmaceutical industry to explode must be hidden in the unmet clinical needs, which are the directions that pharmaceutical companies need to continue to cultivate.
Small, Mid-size Biotechs Could See M&A Action in H2 - PwC
"Weight-loss miracle drug" has new benefits. Research shows that GLP-1 drugs may help reduce the risk of cancer.
The Centers for Disease Control and Prevention (CDC) in the USA states that obesity increases the risk of developing 13 cancers, while the latest research examines the health records of diabetes patients and finds that some diabetes treatments may help prevent obesity-related cancers.
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
What's Going On With Eli Lilly Shares Friday?
Eli Lilly and Co. (NYSE:LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know.What's Happening: Morgan Stanley has maintained its Overweight rating on Eli Lill
Shares of Lilly and Novo Nordisk Are Trading Higher Following a Study Showing Patients Taking GLP-1 Treatments Have a Reduced Risk of Developing Obesity-related Cancers.
Shares of Lilly and Novo Nordisk Are Trading Higher Following a Study Showing Patients Taking GLP-1 Treatments Have a Reduced Risk of Developing Obesity-related Cancers.
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
In a study published in JAMA Network, patients with type 2 diabetes taking GLP-1 treatments have a reduced risk of developing ten types of obesity-related cancers compared to those on insulin and othe
Merck & Co Unusual Options Activity
Financial giants have made a conspicuous bearish move on Merck & Co. Our analysis of options history for Merck & Co (NYSE:MRK) revealed 8 unusual trades.Delving into the details, we found 12% of trade
Executive Reshuffles: NIO, Pfizer and Spirit Airlines in Focus